Table 3.
Clinico-pathological parameters of 300 patients with stage I NSCLC after curative resection in regard to the preoperative CRP level. Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease; CKD, chronic kidney disease; CHD, coronary heart disease; CRP, C-reactive protein.
| Criterion | All Cases | CRP ≤ 5 mg/L | CRP > 5 mg/L | p Value |
|---|---|---|---|---|
| n = 300 (100%) | n = 209 (70%) | n = 91 (30%) | ||
| Age (years; mean) | 66.0 (60.1–72.2) | 64.9 | 66.3 | 0.870 |
| Weight (kg; mean) | 75 (65–85) | 74.8 | 78.3 | 0.976 |
| BMI (kg/m2; mean) | 26.2 (23.5–28.6) | 26.0 | 27.1 | 0.979 |
| Gender | ||||
| Male | 187 (62%) | 124 (59%) | 63 (69%) | 0.104 |
| Female | 113 (38%) | 85 (41%) | 28 (31%) | |
| Smoking Status | ||||
| Yes | 199 (66%) | 137 (66%) | 62 (68%) | 0.664 |
| No | 101 (34%) | 72 (34%) | 29 (32%) | |
| COPD | ||||
| Yes | 126 (42%) | 84 (40%) | 42 (46%) | 0.336 |
| No | 174 (58%) | 125 (60%) | 49 (54%) | |
| PAD | ||||
| Yes | 25 (8%) | 18 (9%) | 7 (8%) | 0.791 |
| No | 275 (92%) | 191 (91%) | 84 (92%) | |
| CKD | ||||
| Yes | 17 (6%) | 11 (5%) | 6 (7%) | 0.647 |
| No | 283 (94%) | 198 (95%) | 85 (93%) | |
| CHD | ||||
| Yes | 41 (14%) | 18 (9%) | 23 (25%) | <0.0001 |
| No | 259 (86%) | 191 (91%) | 68 (75%) | |
| Alcohol abuse | ||||
| Yes | 136 (45%) | 91 (44%) | 45 (49%) | 0.345 |
| No | 164 (55%) | 118 (56%) | 46 (51%) | |
| Albumin (g/dL) | 0.422 | |||
| Albumin < 3.5 g/dL | 21 (7%) | 13 (6%) | 8 (9%) | |
| Albumin ≥ 3.5 g/dL | 279 (93%) | 196 (94%) | 83 (91%) | |
| Histology | ||||
| Adenocarcinoma | 191 (64%) | 140 (67%) | 51 (56%) | |
| Squamous cell | 95 (32%) | 57 (27%) | 38 (42%) | 0.013 |
| Adenosquamous | 2 (1%) | 1 (1%) | 1 (1%) | |
| Large cell | 2 (1%) | 2 (1%) | 0 (0%) | |
| Other | 10 (3%) | 9 (4%) | 1 (1%) | |
| Grading | ||||
| G1 | 55 (18%) | 44 (21%) | 11 (12%) | 0.172 |
| G2 | 131 (44%) | 87 (42%) | 44 (48%) | |
| G3 | 114 (38%) | 78 (37%) | 36 (40%) | |
| Tumor size | ||||
| T1a | 116 (39%) | 90 (43%) | 26 (29%) | 0.018 |
| T1b | 78 (26%) | 57 (27%) | 21 (23%) | 0.446 |
| T2a | 106 (35%) | 62 (30%) | 44 (48%) | 0.002 |
| Tumor stage | ||||
| IA | 194 (65%) | 147 (70%) | 47 (52%) | 0.002 |
| IB | 106 (35%) | 62 (30%) | 44 (48%) | |
| Lymphatic invasion | ||||
| Yes | 80 (27%) | 52 (25%) | 28 (31%) | 0.289 |
| No | 220 (73%) | 157 (75%) | 63 (69%) | |
| Vascular invasion | ||||
| Yes | 28 (9%) | 14 (7%) | 14 (15%) | 0.017 |
| No | 272 (91%) | 195 (93%) | 77 (85%) | |
| Surgical procedure | ||||
| Lobectomy | 279 (93%) | 195 (93%) | 84 (92%) | 0.756 |
| Bilobectomy | 8 (3%) | 4 (2%) | 4 (5%) | 0.220 |
| Sleeve Lobectomy | 11 (4%) | 8 (4%) | 3 (3%) | 0.822 |
| Pneumonectomy | 2 (1%) | 2 (1%) | 0 (0%) | 0.349 |